
Phase 2 trial of oncolytic immunotherapy launches in BCG-unresponsive NMIBC
The first patient has been dosed in a phase 2 trial (NCT06971614) investigating MVR-T3011, an oncolytic immunotherapy for patients with BCG-unresponsive high-risk non–muscle invasive bladder cancer (NMIBC), ImmVira announced in a news release.1 According …